Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Interest Income
Income earned on cash, deposits, and investments held by the company.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $793K rose 24.9% year over year, ahead of the -27.6% change in trailing-twelve-month interest income. Sequentially, it rose 38.2% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.
Context
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +24.9% holds above the trailing-twelve-month pace of -27.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 2.68M USD
- Year-over-year change
- -43.4%
- 4-year CAGR
- +123.2%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.68M | -43.4% |
| FY2024 | 2024-12-31 | 4.74M | -32.9% |
| FY2023 | 2023-12-31 | 7.06M | +261.1% |
| FY2022 | 2022-12-31 | 1.95M | +1709.3% |
| FY2021 | 2021-12-31 | 108K | — |
Interest Income vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 interest income of $2.84M is the 6th highest of the 11 companies compared; the peer median is $4.21M.
- Its year-over-year change of -27.6% is the 3rd highest of 9, against a peer median of -37.7%.
- Interest income amounts to 1262.2% of revenue for TNYA, versus a peer median of 22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.24M | -44.8% | +81.0% | 25.3% | |
| LTM Mar 2026 | $8.9M | -24.3% | +82.0% | 12.9% | |
| LTM Mar 2026 | $7.8M | -35.9% | +15.5% | 27.6% | |
| LTM Mar 2026 | $7.08M | -30.1% | +10.6% | — | |
| LTM Mar 2026 | $5.6M | +18.8% | +134.5% | 38.5% | |
| LTM Mar 2026 | $2.84M | -27.6% | +11.1% | 1262.2% | |
| LTM Mar 2026 | $2.83M | -58.0% | +9.3% | 20.4% | |
| LTM Mar 2026 | $2.26M | -39.6% | -0.5% | 111.9% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | +20.3% | 0.0% | |
| LTM Mar 2026 | -$411.45M | -18576.2% | +44.2% | — | |
| Peer median (excluding TNYA) | $4.21M | -37.7% | +20.3% | 22.9% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.